usp37 Antibody

What is USP37 and why is it important in cellular research?

USP37 is a deubiquitinase (molecular weight ~110 kDa) that catalyzes the removal of ubiquitin from protein substrates. It plays crucial roles in multiple cellular processes:

• Cell cycle regulation: Antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by deubiquitinating cyclin-A (CCNA1 and CCNA2), promoting S phase entry

• DNA replication: Maintains active replisomes on S-phase chromatin by preventing premature CMG helicase unloading

• DNA damage response: Deubiquitinates and stabilizes BLM helicase after DNA double-strand breaks

• Mitotic progression: Regulates mitotic spindle assembly by stabilizing WAPL through deubiquitination

• Cell migration: Promotes cell migration by deubiquitinating EMT-inducing transcription factor SNAI

USP37's disruption leads to replication fork stalling, genome instability, and increased sensitivity to replication stress agents, making it a significant target for understanding fundamental cellular processes and potential therapeutic interventions.

What applications are available for USP37 antibodies in research?

USP37 antibodies can be utilized in multiple experimental applications, with varying effectiveness:

For optimal results, application-specific validation is recommended, especially when antibodies are utilized in novel experimental contexts.

How should I select the appropriate USP37 antibody for my experimental design?

Selection criteria should include:

• Target epitope region:

  • N-terminal (aa 1-300) antibodies may be useful for studying interactions with CDC45, as USP37's Pleckstrin-Homology Domain binds CDC45

  • Middle region antibodies may detect different functional domains

  • Full-length antibodies offer broadest detection capabilities

• Species reactivity:

  • Confirm cross-reactivity with your experimental model (human, mouse, rat, Xenopus)

  • Human USP37 antibodies may cross-react with other species due to sequence homology (e.g., 87% with mouse, 91% with dog, 94% with bovine)

• Validation data:

  • Prioritize antibodies with robust validation in your specific application

  • Look for antibodies validated in knockout/knockdown studies

  • Consider published literature citations (e.g., Bethyl Laboratories antibody has 5 citations)

• Specific applications:

  • For deubiquitination assays, ensure the antibody can detect both unmodified and ubiquitinated forms of USP37

  • For cell-cycle studies, verify detection in different cell cycle phases where USP37 may be phosphorylated

What controls should I include when using USP37 antibodies in my experiments?

Robust experimental design requires appropriate controls:

• Positive controls:

  • Cell lines with known USP37 expression (e.g., U2OS, 293T, RPE1)

  • Tissue samples with validated USP37 expression (e.g., brain tissue, spleen tissue)

  • Recombinant USP37 protein (full-length or fragments)

• Negative controls:

  • USP37 knockdown samples (siRNA or CRISPR-Cas9)

  • USP37 knockout cell lines or tissues

  • Secondary antibody-only controls to assess non-specific binding

• Specificity controls:

  • Detection of expected molecular weight (~110 kDa)

  • Blocking peptide competition assays

  • Comparison with multiple USP37 antibodies targeting different epitopes

• Loading/processing controls:

  • Housekeeping proteins for normalization in Western blots

  • Tissue architecture markers in IHC experiments

  • Nuclear counterstains for immunofluorescence studies

How can USP37 antibodies be used to study DNA replication and genome stability?

Recent research reveals USP37's critical role in DNA replication, offering several experimental approaches:

• Replisome integrity analysis:

  • Use combined immunoprecipitation with USP37 antibodies followed by immunoblotting for CMG components (MCM2-7, CDC45, GINS1-4)

  • Monitor chromatin-bound MCM levels and EdU incorporation by flow cytometry after USP37 depletion or inhibition

  • Pulse-label cells with EdU, then perform proximity ligation assays between USP37 and active replication machinery

• Deubiquitination assays:

  • Co-immunoprecipitate USP37 with MCM7 to assess its deubiquitination activity on the CMG helicase

  • Compare wild-type USP37 with catalytically inactive C350S mutant in rescue experiments

  • Use K48-specific ubiquitin antibodies to monitor USP37-mediated removal of proteasome-targeting ubiquitin chains

• Replication stress response:

  • Assess USP37's protective role during oncogene-induced replication stress using hydroxyurea or aphidicolin treatment

  • Measure stalled replication forks and replication fork progression with DNA fiber assays after USP37 depletion

  • Investigate synthetic lethality between USP37 inhibition and ATR checkpoint kinase inhibitors

• Genetic suppression experiments:

  • Test whether CUL2LRR1 or TRAIP depletion can rescue phenotypes associated with USP37 loss

  • Examine how USP37 protects cells from different types of DNA replication stress (synthesis defects vs. topological stress)

How can I investigate USP37's role in cell cycle regulation using antibody-based methods?

The following methodological approaches can be utilized:

• Cell cycle synchronization studies:

  • Monitor USP37 expression, phosphorylation, and localization across cell cycle phases using immunoblotting and immunofluorescence

  • Use phospho-specific antibodies to detect Ser-628 phosphorylation during G1/S phase, which maximizes USP37's deubiquitinase activity

  • Compare USP37 levels in different cell cycle compartments (cytoplasmic vs. nuclear fractions)

• Target protein interaction analysis:

  • Perform co-immunoprecipitation with USP37 antibodies to detect interactions with known binding partners (Cyclin A, CDH1, β-TRCP1/2)

  • Use proximity ligation assays to visualize USP37-cyclin interactions during cell cycle progression

  • Investigate how phosphorylation affects USP37's interaction with target proteins

• Functional rescue experiments:

  • Express siRNA-resistant versions of USP37 in depleted cells to rescue cell cycle defects

  • Compare wild-type USP37 with catalytically inactive mutants in restoration of normal cell cycle progression

  • Monitor deubiquitination of specific substrates (e.g., cyclins) in complementation experiments

• Cancer dependency analysis:

  • Correlate USP37 expression with cell dependency scores from DepMap data

  • Investigate synthetic lethality between USP37 inhibition and oncogene expression (e.g., cyclin E, c-MYC)

  • Develop antibody-based detection methods for USP37 overexpression in cancer samples

How should I optimize Western blot protocols for USP37 detection?

Optimizing Western blot protocols for USP37 detection requires several considerations:

• Sample preparation:

  • Include protease inhibitors and deubiquitinase inhibitors (N-ethylmaleimide) in lysis buffers

  • For detecting ubiquitinated forms, add proteasome inhibitors (MG132) before cell lysis

  • Separate nuclear and cytoplasmic fractions for compartment-specific analysis

• Electrophoresis and transfer conditions:

  • Use lower percentage gels (6-8%) for better resolution of high-molecular-weight USP37 (~110 kDa)

  • Consider gradient gels when detecting both unmodified and ubiquitinated forms

  • Optimize transfer conditions for large proteins (longer transfer times, lower current)

• Antibody incubation:

  • Test dilution ranges (typically 1:2000-1:16000 for most USP37 antibodies)

  • Optimize incubation time and temperature (4°C overnight often yields better results than room temperature)

  • Consider using milk-free blocking solutions as some antibodies perform better with BSA-based blockers

• Detection strategies:

  • For low-abundance samples, use high-sensitivity chemiluminescent substrates

  • Consider fluorescent secondary antibodies for quantitative analysis

  • When studying modified forms, strip and reprobe with total USP37 antibodies

How do I troubleshoot non-specific binding or false negatives with USP37 antibodies?

Common challenges and solutions include:

• Non-specific bands:

  • Increase antibody dilution (start with manufacturer's recommended range, then optimize)

  • Use more stringent washing conditions (increase salt concentration or detergent)

  • Pre-absorb antibody with cell lysates from USP37-depleted cells

  • Confirm specificity with knockout/knockdown controls

• Weak or no signal:

  • Verify USP37 expression in your sample type (consult published data or RNA databases)

  • Test multiple antibodies targeting different epitopes

  • Optimize protein extraction methods (different lysis buffers may yield better results)

  • Increase protein loading or use concentration methods for low-abundance samples

• Inconsistent results across experiments:

  • Standardize lysate preparation protocols

  • Include positive control samples in each experiment

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Consider lot-to-lot variations in antibody production

• Technical considerations:

  • Ensure proper antigen retrieval for IHC applications (both pH 6.0 citrate and pH 9.0 TE buffers have been reported effective)

  • For immunofluorescence, optimize fixation methods (paraformaldehyde vs. methanol)

  • In IP experiments, test different antibody-to-lysate ratios (0.5-4.0 μg antibody per 1-3 mg lysate)

How can I use USP37 antibodies to investigate its role in DNA damage response pathways?

Recent publications highlight USP37's involvement in DNA damage response through several mechanisms:

• Double-strand break (DSB) response analysis:

  • Monitor USP37 localization to DNA damage sites by immunofluorescence after inducing DSBs

  • Investigate ATM-mediated phosphorylation of USP37 following DNA damage

  • Study USP37-BLM interaction using co-immunoprecipitation and proximity ligation assays

• Checkpoint activation assessment:

  • Examine how USP37 depletion affects CHK1 stability and phosphorylation status during replication stress

  • Use USP37 antibodies to monitor its recruitment to stalled replication forks

  • Investigate synthetic lethality between USP37 depletion and ATR inhibitors

• Homologous recombination (HR) analysis:

  • Assess HR efficiency using reporter assays in USP37-depleted vs. control cells

  • Monitor RAD51 focus formation after DNA damage in USP37-deficient cells

  • Investigate BLM recruitment to damage sites in the presence/absence of USP37

• Damage-specific protein modification:

  • Compare USP37 phosphorylation patterns following different types of DNA damage

  • Examine how DNA damage affects USP37's interaction with its substrates

  • Study USP37-dependent deubiquitination of repair factors in different damage contexts

What approaches can I use to analyze USP37's enzyme activity and substrate specificity?

USP37's deubiquitinase activity can be studied through several methodological approaches:

• In vitro deubiquitination assays:

  • Compare wild-type USP37 with catalytically inactive C350S mutant in deubiquitination assays

  • Use ubiquitinated MCM7 as substrate to assess USP37's ability to remove ubiquitin chains

  • Employ linkage-specific ubiquitin antibodies (K11, K48) to determine chain-type preferences

• Substrate identification and validation:

  • Perform immunoprecipitation of USP37 followed by mass spectrometry to identify interacting proteins

  • Validate candidate substrates through co-immunoprecipitation and deubiquitination assays

  • Examine substrate stability in cells expressing wild-type vs. catalytically inactive USP37

• Structure-function analysis:

  • Use domain-specific antibodies to investigate different functional regions of USP37

  • Study how the PH domain mediates interaction with CDC45 and the CMG helicase

  • Examine how the disordered linker connecting the PH domain to the catalytic domain affects substrate access

• Developmental and tissue-specific analysis:

  • Compare USP37 expression and activity across different tissues (brain, spleen)

  • Investigate species-specific differences in USP37 function using cross-reactive antibodies

  • Study USP37's role in cancer progression through immunohistochemistry of tumor samples